___

• 1.Kaimal S, Thappa DM. Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009; 75(2):126–35. 2.Poojabylaiah M, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J. Relapses in multibacillary leprosy patients after Multidrug therapy. Leprosy Review 2008; 79 (3):320-324. 3. http://www.who.int/wer/2013/wer8835.pdf?ua=1 4.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202011-12.pdf 5.http://nlep.nic.in/pdf/ProgressReport2010-11.pdf 6.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202012-13.pdf 7.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202013-14.pdf 8.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202014-15%20-.pdf 9.http://nlep.nic.in/pdf/revised%20annual%20report%2031st%20March%202015-16.pdf 10.http://www.searo.who.int/entity/global_leprosy_programme/publications/8th_expert_comm_2012.pdf 11.Suzuki K, Udono T, Fujisawa M, Tanigawa K, Idani G, Ishii N. Infection during infancy and long incubation period of leprosy suggested in a case of a chimpanzee used for medical research. J Clin Microbiol 2010; 48(9):3432-3434. 12.Barker LP. Mycobacterium leprae interactions with the host cell: recent advances. Indian J Med Res 2006; 123:748-759. 13.Feldman M. The location dynamics of the US Biotech Industry: Knowledge externalities and the Anchor Hypothesis. J Industry Innovation 2003; 10 (3): 311-29. 14.Poojabylaiah M, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J. Relapses in multibacillary leprosy patients after multidrug therapy. Lepr Rev 2008; 79(3):320–4. 15.Lwin K, Sundaresan T, Gyi MM, et al. BCG vaccination of children against leprosy: fourteen year findings of the trial in Burma. Bull World Heal Organ. 1985 ;63(6):1069-1078. 16. The SAGE Working Group on BCG Vaccines and WHO Secretariat. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. (available at: http://www.who.int/immunization/sage/meetings/2017/october/1_BCG_report_revised_version_online.pdf. 17.Scheelbeek PFD, Balagon MVF, Orcullo FM, Maghanoy AA, Abellana J, Saunderson PR. A Retrospective Study of the Epidemiology of Leprosy in Cebu: An Eleven-Year Profile. PLoS Negl Trop Dis 2013; 19;7(9): e2444. doi: 10.1371/journal.pntd.0002444 18.Reddy S, Brown T, Drobniewski F. Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by INNO-LiPA Rif. TB assay: Retrospective analyses of Health Protection Agency National Mycobacterium Reference Laboratory data. J Med Microbiol 2010; 59(5):563-566. 19.Maghanoy A, Mallari I, Balagon M, Saunderson P. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines. Lepr Rev 2011; 82(1):65-69. 20.Waters MF, Rees RJ, Laing AB, et al. The rate of relapse in lepromatous leprosy following completion of twenty years of supervised sulphone therapy. Lepr Rev 1986; 57(0305-7518):101-109. 21.De Medeiros Brito MDF, Gallo MEN, Ximenes RAA. O retratamento por recidiva em hanseníase. An Bras Dermatol 2005; 80(3):255-260. (English Abstarct) 22. Pandey A, Uddin MJ, Patel R. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002). Lepr Rev 2005; 76(2):112-118. 23.Oh S, Paik HY, Ju D. Dietary Habits, Food Intake and Functional Outcomes in Those with a History of Hansen’s Disease in Korea’. Int J Lepr 1998; 66(I):34–42. 24.WHO. Guidelines for global surveillance of drug resistance in leprosy. World Heal Organ [Internet]. 2009;33. Available at: http://www.leprosy-ila.org/site/view/drug_resistance_guidelines2009_2.pdf 25.Li HY, Hu LF, Huang WB, et al. Risk of relapse in leprosy after fixed-duration multidrug therapy. Int J Lepr Other Mycobact Dis 1997; 65(2):238-245. 26.Gupta UD, Katoch K, Singh HB, Natrajan M, Katoch VM. Persister studies in leprosy patients after multi-drug treatment. Int J Lepr Other Mycobact Dis 2005; 73(2):100-104. 27.Turankar RP, Lavania M, Chaitanya VS, et al. Single nucleotide polymorphism-based molecular typing of M. leprae from multicase families of leprosy patients and their surroundings to understand the transmission of leprosy. Clin Microbiol Infect 2014; 20(3):O142-O149. 28.da Silva Rocha A, Cunha M das G, Diniz LM, et al. Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients. J Clin Microbiol 2012; 50(6):1912-1917. 29.Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev 2005; 76(3):241-252. 30.Sibley LD, Franzblau SG, Krahenbuhl JL. Intracellular fate of Mycobacterium leprae in normal and activated mouse macrophages. Infect Immun 1987; 55(3):680-685. 31.Kar HK, Sharma P. New lesions after MDT in PB and MB leprosy: a report of 28 cases. Indian J Lepr 80(3):247-255. 32.Abdul KS. An analysis of relapsed leprosy cases. Indian J Dermatol Venereol Leprol 2000; 66(3):126-128.